Correlation Engine 2.0
Clear Search sequence regions

To evaluate the test-retest reliability of a device that measures urinary sensation during cystometry, and to use that device to determine whether treatment of overactive bladder syndrome (OAB) with solifenacin is associated with a change in urinary sensation. Overall 15 women were recruited for this study, ten women with OAB and urodynamically demonstrated detrusor overactivity and five controls without OAB underwent filling cystometry twice with contemporaneous, continuous recording of urinary sensation. Women with OAB received solifenacin 10 mg daily during the weeks between testing. We compared the areas under the initial and repeat sensation-volume curves. While taking solifenacin, the maximum cystometric capacity increased from 329 ± 168 ml to 464 ± 123 ml (P < 0.002), and the area under the bladder volume-sensation curve decreased (P < 0.0001). Untreated controls did not exhibit these changes. We present psychometric data demonstrating improved bladder sensation during the treatment of OAB with solifenacin. If clinical correlations are confirmed by future study, such urinary sensation measures may prove useful as assessment, treatment predictor, or outcome measures in OAB research and/or clinical care.


Lior Lowenstein, Kimberly Kenton, Elizabeth R Mueller, Linda Brubaker, Edmond Sabo, Ramón A Durazo-Arivzu, Mary P Fitzgerald. Solifenacin objectively decreases urinary sensation in women with overactive bladder syndrome. International urology and nephrology. 2012 Apr;44(2):425-9

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 21993768

View Full Text